HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Director Ignores Proposed Funding Based On HHS Goals In Budget Request

This article was originally published in The Tan Sheet

Executive Summary

Francis Collins tells a House Appropriations subcommittee that a proposed decrease in NIH funding going toward “advancing scientific knowledge and innovation” will not affect how grants and research dollars are allocated.

You may also be interested in...



FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation

A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. In news applauded by the device industry, the bill would also make available $85 million in previously sequestered FDA user fees.

US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval

Draft guidance gives recommendations for conducting one randomized controlled trial to generate the evidence for accelerated approval and confirm clinical benefit.

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

Any program changes would not occur until after a thorough assessment, the agency said.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel